NCT01466231

Everolimus in Refractory Testicular Germ Cell Cancer

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: National Cancer Institute, Slovakia · Other Government
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements. Feasibility of surgical resection will be assessed after every 2 cycles of the treatment in patients with partial response.

Detailed description

Treatment Schedule: Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. Estimated duration of treatment: Until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements. Feasibility of surgical resection will be assessed after every 2 cycles of the treatment in patients with partial response.

Conditions

• Germ Cell Tumor

Interventions

Type	Name	Description
DRUG	Everolimus	Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.

Timeline

• Start date: 2011-11-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2011-11-07
• Last updated: 2016-01-12

Locations

1 site across 1 country: Slovakia